Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 3:33 PM
Ignite Modification Date:
2025-12-24 @ 3:33 PM
NCT ID:
NCT01597492
Eligibility Criteria:
Key Inclusion Criteria:
* Clinical diagnosis of SLE by American College of Rheumatology (ACR) criteria.
* Active SLE disease.
* Autoantibody-positive.
* Have antibodies with titers \>1.0 microgram (mcg)/mL to no more than 9 of the 23 serotypes present in the pneumococcal vaccine.
* Have the ability to understand the requirements of the study, provide written informed consent, and comply with the study protocol procedures.
Key Exclusion Criteria:
* Pregnant or nursing.
* Have received any prior treatment with belimumab.
* Have received a live vaccine within the past 30 days.
* Have received a pneumococcal vaccination with the past 5 years.
* Have a history of severe allergic reaction to a vaccine, contrast agents (such as those used for x-rays and CT scans), or biological medicines.
* Have required management of an infection or have had infections that keep coming back within the past 60 days.
* Hepatitis B: Serologic evidence of Hepatitis B (HB) infection based on the results of testing for HB surface antigen (HBsAg) and anti-HB core antibody (anti-HBc):
* Subjects positive for HBsAg are excluded.
* Subjects negative for HBsAg but positive for anti-HBc, regardless of anti-HBs antibody status, are excluded.
* Hepatitis C: Positive test for Hepatitis C antibody.
* Known human immunodeficiency virus (HIV) infection.
* Have current drug or alcohol abuse or dependence.
* Have a Grade 3/4 immunoglobulin (Ig)G deficiency (IgG level \<400 milligrams \[mg\]/ deciliter \[dL\]) or IgA deficiency (IgA level \<10 mg/dL).
* Subjects who have evidence of serious suicide risk including any history of suicidal behavior in the last 6 months and/or suicidal ideation with some intent to act in the last 2 months or who in the investigator's judgment, pose a significant suicide risk.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT01597492
Study Brief:
Protocol Section:
NCT01597492